Metraipolis › archive › dc_d07cff98b77d

Real-world efficacy and safety of inetetamab-based therapy in HER2-positive metastatic breast cancer patients with prior exposure to trastuzumab — Europe PMC PMID:40963875

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40963875
DOI
10.3389/fonc.2025.1496371
License (as archived)
solo-consultazione
Archived
2026-11-10T04:08:03.805Z
SHA-256 of the archived text
0b288e427dcdba9b277d3f21f4ea74e1e9e3da9002f5c105a76112c95c54392f
Stable URL of this page
https://metraipolis.com/documento/dc_d07cff98b77d

How to cite

Real-world efficacy and safety of inetetamab-based therapy in HER2-positive metastatic breast cancer patients with prior exposure to trastuzumab — Europe PMC PMID:40963875 — Europe PMC (en), https://europepmc.org/article/MED/40963875 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d07cff98b77d (Metraipolis archive dc_d07cff98b77d, sha256 0b288e427dcdba9b277d3f21f4ea74e1e9e3da9002f5c105a76112c95c54392f)
BibTeX
@misc{dcd07cff98b77d,
  title = {Real-world efficacy and safety of inetetamab-based therapy in HER2-positive metastatic breast cancer patients with prior exposure to trastuzumab — Europe PMC PMID:40963875},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40963875},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d07cff98b77d; sha256 0b288e427dcdba9b277d3f21f4ea74e1e9e3da9002f5c105a76112c95c54392f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40963875. Agents can read the archived copy with the MCP tool read_document.